Dowling v. A.R.T. Inst. of Wash., Inc.

372 F. Supp. 3d 274
CourtDistrict Court, D. Maryland
DecidedMarch 6, 2019
DocketCivil Action No. PX-18-0117
StatusPublished
Cited by7 cases

This text of 372 F. Supp. 3d 274 (Dowling v. A.R.T. Inst. of Wash., Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dowling v. A.R.T. Inst. of Wash., Inc., 372 F. Supp. 3d 274 (D. Md. 2019).

Opinion

Paula Xinis, United States District Judge

This case concerns the heartbreak of infertility compounded by the suffering of an infant born with a severe congenital disorder. In filing this suit, Plaintiff Jonathan Dowling lays bare his family's difficult journey. Dowling asserts that the embryology practice where Dowling and his wife sought assistance caused the couple unwittingly to agree to a high-tech in-vitro fertilization procedure which, in their view, led to their infant son's severe and ultimately fatal birth defects. Before this opinion unfolds, it is important to recognize the depth of the Dowlings' suffering and loss.

Now the Court must review the Complaint for legal sufficiency. Defendants A.R.T. Institute of Washington, Inc. and Erika Cullingford (collectively, "Defendants") have moved to dismiss the Complaint or in the alternative for summary judgment. ECF No. 7. Dowling has opposed the motion and moves for partial summary judgment in his favor. ECF No. 21. The Court held a hearing on February 25, 2019. For the following reasons, the Court denies Defendants' motion and grants Dowling's motion in part.

I. Background

Jonathan Dowling ("Dowling") is a Lieutenant Commander in the Judge Advocate General's Corps of the United States Navy. ECF No. 1 at 2. For quite some time, he and his wife Kathryn had wanted a baby, and tried a variety of fertility treatments to no avail. Id. ¶ 18. At some point, the couple chose to pursue in vitro fertilization ("IVF") at the Walter Reed National Military Medical Center ("WRNMMC") in Bethesda, Maryland. Id. WRNMMC contracted with the A.R.T. Institute of Washington, Inc. ("A.R.T.") to provide embryology services to military servicemembers and their families. Id. ¶¶ 14, 19-20.

In pursuit of IVF, the Dowlings met with medical staff from WRNMMC and A.R.T. on February 21, 2012. Id. ¶ 36. At this meeting, the Dowlings signed a written consent form pertaining to IVF generally and to a specific type of embryological service called intracytoplasmic sperm injection ("ICSI"). Id. ¶ 37. ICSI is a procedure where trained medical personnel identify from the male partner's sperm sample a single sperm that provides the best opportunity for fertilization, and then injects that single sperm via a pipette directly into the egg. ECF No. 1-6 at 6. ICSI is often used when "the sperm may *279not be judged adequate to achieve fertilization using conventional insemination (putting the eggs and sperm closely together)." Id.

At the initial meeting with the Dowlings, A.R.T. presented the ICSI consent form for their review and signatures. The form memorialized that the Dowlings understood how ICSI worked, in that prior to an IVF-ICSI cycle, Dowling would provide a semen sample "for analysis by the andrology laboratory." Id. at 1. If the sample was "not judged adequate to achieve fertilization using conventional insemination" or "where fertilization has failed or was substantially reduced in prior IVF cycles," ICSI would offer a better chance of conceiving. Id. at 6.

As part of the ICSI consent form, the Dowlings were apprised of several risks and precautions. Specifically, under a prominent heading in boldface type which read "We understand that ICSI may involve the following risks or disadvantages," the consent form expressly warned that "[t]his technology is relatively new (started 1992), and there may be unknown risks to the baby or mother." ECF No. 1-6 at 6-7. The consent further warned that "[w]hile there seems to be no higher overall incidence of congenital malformations in children born after ICSI ... the risk cannot be totally ruled out." Id. at 7. The consent form confirmed that the Dowlings knew and understood all the terms: "We hereby attest that we have read the above referenced consent forms, or that they have been read to us, so that we understand it completely. We further attest that any and all questions of ours regarding all procedures have been answered to our complete satisfaction." Id. at 12.

On March 7, 2012, Dowling provided a semen sample for evaluation to A.R.T. junior embryologist Erika Cullingford ("Cullingford"). ECF No. 1 ¶¶ 28, 47. Dowling noted on the accompanying Semen Analysis Form that he had begun taking paroxetine, commonly known as Paxil, that same day. Id. ¶¶ 46-47. Cullingford and another A.R.T. employee analyzed his sample and found the sperm's "pre-wash motility" to be 39%, with the "normal value" noted as >40%. Id. ¶ 47; ECF No. 1-9. The form also noted a finding of "ICSI Low initial motility." ECF No. 1-9.

The Dowlings then began their IVF procedure, which included Kathryn Dowling taking hormone stimulants to promote maturation of several eggs at once. Prior to beginning this phase of the IVF process, A.R.T. invoiced the Dowlings for their upcoming IVF cycle, which included a separate charge for ICSI. ECF No. 1 ¶¶ 31, 48. When Kathryn Dowling asked A.R.T. about the charge for ICSI, she was told that the "low initial motility" finding from the March 7, 2012 sperm sample warranted the use of ICSI. Id. ¶ 48. The Dowlings paid the invoice in full. Id. ¶ 49.

On July 6, 2012, the Dowlings returned to WRNMMC for the clinic to retrieve Kathryn Dowling's eggs and collect another semen sample from Dowling for fertilization via ICSI. Id. ¶ 53. Before this day, Dowling had researched the effects of Paxil on conception. Specifically, Dowling had read that using Paxil may lead to increased DNA fragmentation in sperm that could complicate pregnancy and risk abnormalities in the fetus. Id. ¶ 51. Dowling shared these concerns with the WRNMMC medical providers who responded that the risk of Dowling's recent Paxil use was "negligible" in terms of fertilization. Id. ¶¶ 51, 54. Dowling again filled out the A.R.T. Semen Analysis Form, noting that he was taking Paxil and that "Doctor did not provide information on impacts on sperm. Discovered study last night on internet." Id. ¶ 55. According to the study Dowling had found, the likely DNA fragmentation *280in his sperm in July 2012 was 42%, well above the 30% threshold for abnormal DNA fragmentation. Id. ¶ 70. In contrast, when Dowling underwent semen analysis in February 2013, after discontinuing Paxil in October 2012, his DNA fragmentation level was 26%. Id. ¶ 69. In other words, an abnormally high percentage of the sperm sample used for ICSI included damaged sperm attributable to using Paxil.

The Dowlings proceeded with egg retrieval and fertilization. Dowling provided a sperm sample which Cullingford analyzed as having a "prewash motility of 48%" and a "prewash progression of 40%." Id. ¶ 56. Cullingford noted on the Semen Analysis Form that "[t]he sample that has been prepared is of ICSI standards ... due to [l]ow initial motility." Id. Dowling reviewed this form prior to agreement to use ICSI for fertilization. He understood Cullingford's note to mean that the sample he had given that day (July 6, 2012) had low motility. Consequently, he and his wife consented to the ICSI procedure. Id. ¶ 57.

A.R.T. selected twelve individual sperm cells to fertilize twelve eggs retrieved from Kathryn Dowling. Id. ¶ 58. On July 11, 2012, an embryo was transferred to Kathryn Dowling. Id. ¶ 59. Several days later, the Dowlings learned they were pregnant. Id. ¶ 61.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
372 F. Supp. 3d 274, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dowling-v-art-inst-of-wash-inc-mdd-2019.